Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease

Table 2 Patient characteristics of 49 patients with RA

Disease duration (years)	12.3 (9.3 to 15.1) yrs.
Reumatoid factor positive (%)	100%
Anti-CCP positive	79%
DAS-28	2.92 (0.75 to 6.9)
Remission (ACR/EULAR 2010 criteria)	18%
HAQ score	0.18 (0.0 to 1.45)
Sharp van der Heijde score	19 (0 to 103)
Medication	MTX (63%)
	SSZ (16%)
	Anti-TNF (22%)
	Rituximab (2%)
	Leflunomide (6%)
	Azathioprine (3%)
	None (10%)

Disease duration in years. DAS-28 scores were normally distributed. HAQ and Sharp van der Heijde scores were not normally distributed.

ISSN: 1478-6362